Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 71   

Articles published

APPY 3.50 -0.10 (-2.78%)
price chart
Stocks to Keep Your Eyes on Neothetics Inc (NASDAQ:NEOT), Venaxis Inc (NASDAQ ...
Shares of Neothetics Inc (NASDAQ:NEOT) flew +14.58% to $1.20 at 2:06 PM EDT. The stock attained the volume of 2.06 Million shares recently versus average trading volume of 793,682.00 shares.
Venaxis Inc. APPY (US: Nasdaq)
News Venaxis Inc.APPY. No news for APPY in the past two years. Key Stock Data ? P/E Ratio (TTM): The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted ...
Venaxis, Inc. (APPY) Latest Broker Coverage
A number of investment brokers have recently updated their price targets on shares of Venaxis, Inc. (APPY). According to the latest broker reports outstanding on Thursday 9th of June, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...
Latest Analyst Ratings For Venaxis, Inc. (APPY)
Venaxis, Inc. (Venaxis) is an in vitro diagnostic company that is focused on commercializing its blood-based test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children, adolescent and young adults.
Venaxis Inc (APPY) Stock Crashes On FDA's “Not Substantially Equivalent” Response
Venaxis Inc (NASDAQ:APPY) has received "not substantially equivalent" remarks on its blood-based diagnostic test, APPY1, from the US Food and Drug Administration (FDA).
Venaxis' appendicitis test not found equivalent to standard care  Reuters
Venaxis Receives FDA "Not Substantially Equivalent" Response on ...  PR Newswire (press release)
Latest Analyst Reports On Venaxis, Inc.
02/10/2016 - Venaxis, Inc. had its “hold” rating reiterated by analysts at Canaccord Genuity. They now have a USD 0.5 price target on the stock.
Venaxis, Inc. (APPY) Broker Price Targets For The Coming Week  Share Trading News
Venaxis, Inc. (NASDAQ:APPY) Posted Basic Consolidated EPS Of $-0.2826  Equities Focus
INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced By Glancy ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of a class (the “Class”) comprising purchasers of the securities ...
Portfolio Of Healthcare Movers: Valeant Pharmaceuticals International, Inc ...
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) decreased -4.20% to $27.86 while traded 32.87 million shares on 5/18/2016.
Venaxis, Inc. (NASDAQ:APPY) Quarterly Basic Net EPS At 2016-03-31
For the year ended 2016-03-31 Venaxis, Inc. (NASDAQ:APPY) basic consolidated EPS came $-0.2826. Conversely, for the quarter ended 2016-03-31, it was $-0.2826.
Venaxis, Inc. (APPY) Updated Price Targets
01/29/2015 - Venaxis, Inc. was downgraded to “hold” by analysts at Craig-Hallum. Venaxis, Inc. has a 50 day moving average of 3.45 and a 200 day moving average of 2.61.